While many HDAC4 targets have been identified [47,94], we focused on HIF1α, one of the central players of tumor progression and drug response [47,48,49,50] and VEGFA, one of the best-characterized HIF1α targets [69,70,71]. The gene discussed is HIF1A; the disease is neoplasm.